What are MoonLake Immunotherapeutics's total assets?

MoonLake Immunotherapeutics (MLTX) holds $400.4M in total assets, down 21.7% year over year.

How much debt does MoonLake Immunotherapeutics have?

MoonLake Immunotherapeutics carries $100.8M in total debt against $254.0M of shareholders' equity, a debt-to-equity ratio of 0.40.

How much cash does MoonLake Immunotherapeutics have?

MoonLake Immunotherapeutics holds $298.5M in cash and equivalents.

Can MoonLake Immunotherapeutics cover its short-term obligations?

Its current ratio is 8.60 — current assets exceed current liabilities.

Where does MoonLake Immunotherapeutics's balance sheet data come from?

Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

MoonLake Immunotherapeutics MLTX Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$334.52M+85.4%	$180.43M-60.0%	$451.17M+1,042%	$39.51M+391%
Short-term investments	$59.45M-77.8%	$267.6M+347%	$59.84M+83.5%	$32.61M—
Prepaid expenses and other current assets	$1.12M+146%	$453K+151%	$180.79K-43.3%	$319.01K+150%
Total current assets	$421.69M-11.1%	$474.29M-7.8%	$514.17M+572%	$76.51M+694%
Property and equipment, net	$577K-20.1%	$722K+125%	$320.87K+550%	$49.39K+8.0%
Operating lease right-of-use assets	4.6%-292,199,995%	292,200,000%-70,648,000%	362,848,000%+334,590,000%	28,258,000%—
Other non-current assets	$596K—	$0—	——	——
Total noncurrent assets	$2.74M-24.8%	$3.64M-70.5%	$12.37M+3,627%	$331.97K+626%
Total assets	$424.43M-11.2%	$477.93M-9.2%	$526.54M+585%	$76.84M+694%
Accrued expenses	$2.32M-80.8%	$12.1M+74.6%	$6.93M-4.5%	$7.26M+60.6%
Operating lease liabilities, current	$1.23M-10.1%	$1.37M+14.5%	$1.2M+680%	$153.63K—
Income taxes payable	$1.09M+70.4%	$642K+74.5%	$367.98K+235%	$109.83K+71.8%
Total current liabilities	$45.48M+102%	$22.46M+125%	$9.97M+30.0%	$7.67M-63.6%
Long-term debt	$74.1M—	$0—	——	——
Operating lease liabilities, non-current	$374K-74.3%	$1.46M-41.7%	$2.5M+1,839%	$128.95K—
Operating Lease Liabilities (Total)	$1.61M-43.2%	$2.83M-23.5%	$3.7M+1,209%	$282.58K-35.0%
Total noncurrent liabilities	$74.47M+3,482%	$2.08M-32.6%	$3.08M+650%	$411.16K+71.4%
Total liabilities	$119.95M+389%	$24.54M+88.1%	$13.05M+61.6%	$8.08M-62.1%
Additional paid-in capital	$766.78M+13.2%	$677.42M+11.1%	$609.97M+372%	$129.19M+207%
Retained earnings	-$462.91M-96.5%	-$235.59M-102%	-$116.66M-44.6%	-$80.65M-50.3%
Accumulated other comprehensive income (loss)	$604K-87.9%	$5M+112%	$2.36M+572%	$350.95K+309%
Total stockholders' equity	$304.48M-31.9%	$446.83M-9.9%	$495.68M+914%	$48.9M+520%
Total liabilities and stockholders' equity	$424.43M-11.2%	$477.93M-9.2%	$526.54M+585%	$76.84M+694%
Available-for-Sale Debt Securities - Amortized Cost	$59.17M-81.6%	$321.88M—	——	——
Cash, Cash Equivalents, and Marketable Securities	$59.45M-81.8%	$327.28M—	——	——
Available For Sale Securities Debt Securities Current	$59.45M-77.8%	$267.6M+347%	$59.84M+83.5%	$32.61M—
Cash Cash Equivalents And Short Term Investments	——	——	——	——
Other accounts receivable (net of allowances of $37 in 2026 and $37 in 2025)	$4.87M+71.2%	$2.84M+169%	$1.06M+387%	$217.13K+45.9%
Other Receivables	$4.87M+71.2%	$2.84M+169%	$1.06M+387%	$217.13K+45.9%
Deferred Tax Assets and Other Non-Current Assets	$596K—	$0—	——	——
Investments - Amortized Cost Basis	$59.17M-81.6%	$321.88M—	——	——
Net Investment in Lease	$1.57M-46.4%	$2.92M-19.5%	$3.63M+1,184%	$282.58K—
Deferred contract costs	$587K—	——	——	——
Operating lease right-of-use assets	$1.57M-46.4%	$2.92M-19.5%	$3.63M+1,184%	$282.58K—
Other non-current assets	$596K—	$0—	——	——
Operating Lease Right-of-Use Assets in Other Assets	$1.57M-46.4%	$2.92M-19.5%	$3.63M+1,184%	$282.58K—
Software and Technology Licenses, Net	$596K—	$0—	——	——
Accrued Manufacturing Costs	$2.32M-45.1%	$4.24M+52.4%	$2.78M+151%	$1.11M-21.8%
Accrued Income Taxes, Current	$1.09M+70.4%	$642K+74.5%	$367.98K+235%	$109.83K+71.8%
Compensation and benefits	$2.32M-45.1%	$4.24M+52.4%	$2.78M+151%	$1.11M-21.8%
Trade and other payables	$29.55M+229%	$8.99M+389%	$1.84M+621%	$254.97K-83.8%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Debt Instrument Face Amount	$75M—	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$4.52M—	——	——	——
Defined Benefit Pension Plan Liabilities (Non-Current)	$0-100%	$621K+6.4%	$583.43K+107%	$282.21K+17.7%
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Accrued expenses and other liabilities	$14.69M+21.4%	$12.1M+74.6%	$6.93M-4.5%	$7.26M+60.6%
Total debt	$75.71M+2,576%	$2.83M-23.5%	$3.7M+1,209%	$282.58K-98.2%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Unrealized Gains on Investments	$285K-94.7%	$5.41M—	——	——
Cumulative Cost Basis	$59.17M-81.6%	$321.88M—	——	——
Consultant and other fees	$430K-26.6%	$586K-31.4%	$853.91K+160%	$327.85K+566%
Research and development services and license fees	$4.23M+109%	$2.02M+64.9%	$1.23M—	——
Supply and manufacturing services	$6.62M+47.9%	$4.47M+179%	$1.6M—	——
Gross Unrealized Gains	$285K-94.7%	$5.41M—	——	——
Total	$59.17M-81.6%	$321.88M—	——	——
Available for sale investments	$59.45M-81.8%	$327.28M—	——	——
Common stock, conversion ratio (in shares)	——	——	——	——
Excess of current assets less current liabilities	——	——	——	——
Accreted present value of End of Term Charge	$3.62M—	——	——	——
Debt issuances	$75M—	——	——	——
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$4.52M—	——	——	——
Future pension and postretirement benefit obligations	$0-100%	$621K+6.4%	$583.43K+107%	$282.21K+17.7%
Lessee Operating Lease Liability Payments Due	——	——	——	——
Thereafter	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Long-Lived Assets	$2.14M-41.2%	$3.64M-7.7%	$3.95M—	——
Operating Lease Weighted Average Discount Rate Percent	$0.05-2.1%	$0.05-4.1%	$0.05—	——
Prepaid expenses	$22.86M-2.4%	$23.42M+1,014%	$2.1M-49.7%	$4.18M+188%
Prepaid Insurance	$886K-20.4%	$1.11M+3.3%	$1.08M-23.9%	$1.42M+6,022%
Non-clinical research and clinical development services	$17.36M+22.8%	$14.14M+1,577%	$842.73K-65.5%	$2.44M+346%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	——	——	——	——
Supply and manufacturing services	$3.49M-54.7%	$7.72M+640,232%	$1.21K—	——
Total commitments not yet recognized	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are MoonLake Immunotherapeutics's total assets?: MoonLake Immunotherapeutics (MLTX) holds $400.4M in total assets, down 21.7% year over year.
How much debt does MoonLake Immunotherapeutics have?: MoonLake Immunotherapeutics carries $100.8M in total debt against $254.0M of shareholders' equity, a debt-to-equity ratio of 0.40.
How much cash does MoonLake Immunotherapeutics have?: MoonLake Immunotherapeutics holds $298.5M in cash and equivalents.
Can MoonLake Immunotherapeutics cover its short-term obligations?: Its current ratio is 8.60 — current assets exceed current liabilities.
Where does MoonLake Immunotherapeutics's balance sheet data come from?: Every line is extracted from MoonLake Immunotherapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.